X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Biopharmaceutical research and development has ushered in a decade of innovation in rare disease

By Samantha Hinkle  |    February 28, 2022
This year on Rare Disease Day, we join families and communities around the world building awareness around rare diseases and encouraging patients to share their stories.   Read More

The patient experience: Insurance barriers continue to impede access to health care, especially among the country’s underserved

By Cynthia Hicks  |    February 28, 2022
The second installment of the Patient Experience Survey finds insurer-imposed practices pose significant barriers for Americans as they attempt to access the care they need – and that they are paying...   Read More

New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year

By Megan Van Etten  |    February 24, 2022
Biopharmaceutical companies are working across the industry and around the world to meet the global demand for COVID-19 vaccines. Companies have continued to ramp up their efforts to source needed...   Read More

4 things to know about biopharmaceutical efforts to fight cancer

By Andrew Powaleny  |    February 24, 2022
A recent study published in Nature is a profound reminder of how far we’ve come in the fight against cancer. Authors of the study, which examined the long-term effects of CAR-T cell therapy,...   Read More

Government price setting leaves behind families counting on new medicines

By Nicole Longo  |    February 23, 2022
Rather than pursuing policies that would actually address our broken insurance system and lower costs for patients – while protecting medical innovation – policymakers keep going back to the same,...   Read More

What you need to know about newly authorized COVID-19 antiviral treatments

By Richard Moscicki, M.D.  |    February 22, 2022
In December 2021, the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for the first two oral antivirals for the treatment of certain COVID-19 patients. These...   Read More

Part B 101: Three charts show the program helps control costs for health care system and enrollees

By Nicole Longo  |    February 18, 2022
Medicare Part B covers a wide range of health care services, including physician office visits, hospital outpatient care and medical equipment. It also covers medicines that are usually administered...   Read More

Guest post: Joining forces to combat the COVID-19 mental health crisis

By Guest Contributor  |    February 17, 2022
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...   Read More

Guest Blog: COVID-19 vaccines are the key to keeping kids healthy

By Guest Contributor  |    February 16, 2022
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...   Read More

PhRMA submits comments urging CMS to withdraw coverage proposal

By Lauren Neves  |    February 11, 2022
In comments submitted this week, PhRMA urged the Centers for Medicare & Medicaid Services (CMS) to withdraw its proposed national coverage determination (NCD) for monoclonal antibodies (mAbs) for the...   Read More

340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients

By Nicole Longo  |    February 8, 2022
The 340B program was created 30 years ago to support safety-net clinics and qualifying hospitals by establishing a discounted medicine program funded by biopharmaceutical manufacturers. The aim was...   Read More

Medicaid 101: Three charts on access and spending

By Jasmine Gossett  |    February 3, 2022
Did you know Medicaidand the Children’s Health Insurance Program provide health coverage for more than 83 million vulnerable Americans, including children and their parents, pregnant women, the...   Read More

The importance of timely PDUFA and BsUFA reauthorization

By Lucy Vereshchagina  |    February 3, 2022
Today, PhRMA, along with the U.S. Food and Drug Administration (FDA) and other industry trade associations, will be participating in a congressional hearing with the House Committee on Energy and...   Read More

Government price setting won’t stop insurers from shifting costs to patients

By Nicole Longo  |    February 2, 2022
The drug pricing provisions in the Build Back Better Act (BBBA) would allow the government to set the price of certain medicines in Medicare. This is a misguided approach that threatens future...   Read More

Research and development continues long after a medicine is initially approved

By Jocelyn Ulrich  |    February 1, 2022
The government’s flawed price setting plan under the Build Back Better Act will significantly upend the biopharmaceutical research and development (R&D) process, risking important advances in patient...   Read More

Protecting U.S. innovation abroad to support economic and pandemic recovery

By Ernest Kawka  |    February 1, 2022
PhRMA’s recently submitted comments to the Office of the U.S. Trade Representative (USTR)’s 2022 Special 301 Report reinforce how the United States can confirm its strong commitment to defend...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."